52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Moderna Provides U.S. COVID-19 Vaccine Supply Update
Moderna Confirms Co Is Proposing Filling Vials With Additional Doses Of Vaccine - CNBC
Moderna Said To Seek FDA Clearance To Increase Doses Per Vial To Alleviate Manufacturing Bottleneck- CNBC
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
Biotechnology & Drugs
200 Technology Sq
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Chief Executive Officer, Director
David W. Meline
Chief Financial Officer
Chief Human Resource Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus, and has raised its global COVID-19 vaccine production goal for this year by 100 million doses.
Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus and has raised its global COVID-19 vaccine production goal for this year by 100 million doses.
Israel aims to reopen its economy by April 5 after having vaccinated all its eligible population and is in talks with vaccine makers Pfizer and Moderna to open facilities in the country, Prime Minister Benjamin Netanyahu said on Wednesday.
Takeda Pharmaceutical Co said on Wednesday the first patient had been given Novavax Inc's COVID-19 vaccine candidate in a Japanese clinical trial.
South Africa's health minister said on Tuesday that government advisers had organised COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson (J&J), Pfizer and Moderna shots.
South Africa's health minister said on Tuesday that a committee advising the government had grouped COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson, Pfizer and Moderna shots.
The two COVID-19 vaccines approved for use in the United States have reassuring safety profiles with no concerning new issues found in data collected from the first month of vaccinations, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday.
Pfizer Inc has not yet delivered to the European Union about 10 million COVID-19 vaccine doses that were due in December, EU officials said, leaving it about one-third short of the supply it had expected from the U.S. drugmaker.
The European Commission said on Wednesday it had struck a deal for an extra 150 million doses of Moderna's COVID-19 vaccine this year, nearly doubling the number of shots secured from the U.S. biotech firm for 2021.
* EU SET TO ANNOUNCE FRESH VACCINE DEAL WITH MODERNA - FT Source text: https://on.ft.com/3prZYAN Further company coverage:
Moderna Inc said on Tuesday the release of some of its COVID-19 vaccine doses to the U.S. government have lagged recently because of "short-term delays" in the final stages of production at its contractor Catalent Inc.
Moderna Inc said on Tuesday it was moving forward the supply targets for the second 100 million of its COVID-19 vaccine doses to the United States by a month to May end. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
Canada will receive some doses of Pfizer Inc's COVID-19 vaccine earlier than scheduled and is on track to inoculate the entire population by the end of September, Prime Minister Justin Trudeau said on Friday.
Posts have been circulating on social media claiming that only governments are calling the Pfizer-BioNTech and Moderna COVID-19 vaccines “vaccines”, and that the companies themselves call them “biological agents” and an “Operating System designed to program Humans.” This...
The Qatari health ministry issued an emergency use authorization on Wednesday for Moderna's COVID-19 vaccine, the ministry said in a tweet.
Bulgaria plans to order more than 3 million additional doses of COVID-19 vaccines from Pfizer-BioNTech and Moderna as a precaution against decreased deliveries from AstraZeneca, the government said on Wednesday.
U.S. drugmaker Moderna Inc will supply its COVID-19 vaccine to the governments of Taiwan and Colombia, the company said, providing five million and 10 million doses respectively.
U.S. drugmaker Moderna Inc said on Tuesday it had entered supply agreements for its COVID-19 vaccine with the governments of Taiwan and Colombia for five million doses and 10 million doses, respectively.
South Korea and COVID-19 vaccine maker Moderna Inc are in discussions over a $200 million investment by the U.S. drugmaker to build a vaccine manufacturing factory in the country, a former government minister who was involved in the talks said.
Moderna Inc is in discussions with the South Korean government to potentially invest around $200 million in the country to build a factory, a local newspaper Asia Business Daily reported on Friday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.